Prof. Mariana Michalowski
Departamento de Pediatria, UNIVERSIDADE FEDERA RIO GRANDE DO SUL, Porto Alegre, Rio Grande do Sul, Brazil
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
30Years (1997-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 March 1997 in Physiology & Behavior
Journal Article
DED R Ely
D R Ely
VDV Dapper
V Dapper
JMJ Marasca
J Marasca
JCJ B Corrêa
J B Corrêa
GGG D Gamaro
G D Gamaro
CDC Dalmaz
C Dalmaz
+5
1 April 2006 in Cancer Genetics and Cytogenetics
Journal Article
Mariana MichalowskiFFFlorence de Fraipont
Florence de FraipontSMSylvie Michelland
Sylvie Michelland
NENatascha Entz-Werle
Natascha Entz-Werle
JGJacques Grill
Jacques Grill
DPDominique Plantaz
Dominique Plantaz
+2
1 July 2020 in Hematology, Transfusion and Cell Therapy
Journal Article
DCDaiane Cecconello
Daiane CecconelloMMMariana Rodrigues de Magalhães
Mariana Rodrigues de Magalhães
IWIsabel Cristina Ribas Werlang
Isabel Cristina Ribas Werlang
MLMaria Lucia de Martino Lee
Maria Lucia de Martino Lee
Mariana MichalowskiLDLiane Esteves Daudt
Liane Esteves Daudt
The long-term outcome of acute lymphoblastic leukemia has improved dramatically due to the development of more effective treatment strategies. L-asparaginase (ASNase) is one of the main drugs used and causes death of leukemic cells by systematically depleting the non-essential amino acid asparagine. Three main types of ASNase have been used so far: native ASNase derived from Escherichia coli, an enzyme isolated from Erwinia chrysanthemi and a pegylated form of the native E. coli ASNase, the ASNase PEG. Hypersensitivity reactions are the main complication related to this drug. Although clinical allergies may be important, a major concern is that antibodies produced in response to ASNase may cause rapid inactivation of ASNase, leading to a worse prognosis. This reaction is commonly referred to as "silent hypersensitivity" or "silent inactivation". We are able to analyze hypersensitivity and inactivation processes by the measurement of the ASNase activity. The ability to individualize the ASNase therapy in patients, adjusting the dose or switching patients with silent inactivation to an alternate ASNase preparation may help improve outcomes in those patients. This review article aims to describe the pathophysiology of the inactivation process, how to diagnose it and finally how to manage it.
1 December 2001 in The Canadian Journal of Psychiatry
Journal Article
STSilzá Tramontina
Silzá Tramontina
SMSilvia Martins
Silvia Martins
Mariana MichalowskiCKCarla R Ketzer
Carla R Ketzer
MEMariana Eizirik
Mariana Eizirik
LRLuis A Rohde
Luis A Rohde +1
Objectives: To evaluate the association between DSM-IV conduct disorder (CD) and school dropout in a sample of students from the third and fourth elementary grades at state schools in the capital of the southernmost state of Brazil. Methods: In this case-control study, students that dropped out of schools ( n = 44) and a control group who continued attending schools ( n = 44) were assessed for CD and other prevalent mental disorders, using the Schedule for Affective Disorders and Schizophrenia for School Age Children, Epidemiological Version (K-SADS-E). Results: The prevalence of DSM-IV CD was significantly higher in the school-dropout group than in control subjects ( P < 0.001), both in the entire sample and in a subsample including only subjects under age 12 years ( P = 0.001). Also, the odds ratio (OR) for school dropout was significantly higher in the presence of DSM-IV CD, even after controlling for potential confounding factors (age, estimated IQ, school repetition, family structure, and income) ( P < 0.01). Conclusion: Our results extend to children and young adolescents previous findings from studies of older adolescents, suggesting an association between school dropout and CD.
19 November 2007 in Pediatric Blood & Cancer
Journal Article
Mariana MichalowskiFFFlorence de Fraipont
Florence de FraipontDPDominique Plantaz
Dominique Plantaz
SMSylvie Michelland
Sylvie Michelland
VCValérie Combaret
Valérie Combaret
MFMarie‐Christine Favrot
Marie‐Christine Favrot1 September 2018 in The Lancet Oncology
Journal Article
DCDaiane Cecconello
Daiane CecconelloIWIsabel Cristina Ribas Werlang
Isabel Cristina Ribas Werlang
AAAna Paula Alegretti
Ana Paula Alegretti
MHMonique Cabral Hahn
Monique Cabral HahnMMMariana Rodrigues de Magalhães
Mariana Rodrigues de Magalhães
Mariana Michalowski +7
About Me
Graduated in Medicine from the Federal University of Rio Grande do Sul (1999), with specialization in Pediatric Oncology and Hematology from Université de Lyon I and a PhD in Pediatrics - Pediatric Oncology from Université de Grenoble I (2006), focusing on epigenetic alterations of childhood neuroblastomas and ependymomas. She served as Head of the Pediatric Oncology and Hematology Service at Hospital da Criança Santo Antônio in Porto Alegre (2013-2015). Currently, she is an Adjunct Professor in the Department of Pediatrics and the Graduate Program in Child and Adolescent Health at the Federal University of Rio Grande do Sul. She also serves as Head of the Pediatric Hematology-Oncology Inpatient Unit and the Translational Pediatrics Laboratory at the Hospital de Clínicas de Porto Alegre.
She is an active member of the Pediatric Committee of the Brazilian Association of Hematology and Hemotherapy (ABHH) and the Palliative Care Committee of the Brazilian Society of Pediatrics (SBP). With extensive experience in Pediatrics, with an emphasis on Pediatric Oncology and Hematology, she stands out for her leadership in research projects and guidance of undergraduate and graduate students. Her research has been published in renowned scientific journals, and she regularly participates in international conferences, where she is also an invited speaker.